Cell Lines That Make Their Own Amino Acids

Why It Matters

By enabling cells to synthesize missing amino acids and suppress waste by‑products, bioprocesses can become more efficient, lowering media costs and simplifying feed control. This could accelerate antibody and protein production while improving product consistency.

Key Takeaways

• Engineered CHO cells synthesize threonine and histidine
• New lines eliminate lactate production across conditions
• Ammonia generated only during stationary phase
• Reduced feeding simplifies bioprocessing and cuts waste
• Strategy also validated in HEK293 cells

Pulse Analysis

Chinese Hamster Ovary (CHO) cells have been the workhorse of therapeutic protein manufacturing for decades, but their reliance on complex, precisely timed feeding regimens remains a cost and operational challenge. Conventional media must supply the seven essential amino acids that CHO cells cannot synthesize, and the cells’ metabolism often generates lactate and ammonia, which can inhibit growth and compromise product quality. These waste metabolites force manufacturers to implement tight pH control, additional purification steps, and frequent media adjustments, driving up capital expenditures and reducing overall process robustness.

The DTU team tackled these bottlenecks by inserting biosynthetic pathways for threonine and histidine directly into the CHO genome, allowing the cells to fulfill their own amino‑acid requirements. Simultaneously, they rewired central carbon metabolism to suppress lactate formation and limited ammonia release to the stationary phase, where it is less detrimental. Experimental data showed no detectable lactate across a range of production scenarios and only trace ammonia after growth ceased. Importantly, the same low‑waste phenotype was reproduced in HEK293 cells, suggesting the approach is not cell‑type specific.

From a commercial perspective, self‑sufficient, low‑waste cell lines could shrink media inventories, reduce feed‑stock logistics, and simplify scale‑up, translating into measurable cost reductions for monoclonal antibody and recombinant protein pipelines. Moreover, the cleaner metabolic profile may improve glycosylation consistency and lower downstream purification burdens, enhancing product safety and regulatory appeal. As the researchers expand the amino‑acid repertoire and combine the two engineered traits, the industry could see a new generation of “lean” bioprocesses that accelerate time‑to‑market while maintaining high quality. Adoption will hinge on robust validation and alignment with existing GMP frameworks.